HIND

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025, for ReShape Lifesciences Inc. (trading symbol: RSLS), which is in the process of merging with Vyome Therapeutics, Inc. The combined entity intends to operate as Vyome Holdings, Inc. The company is a physician-led weight-loss solutions provider focusing on the Lap-Band system and the development of the Diabetes Bloc-Stim Neuromodulation device. The filing notes a pending merger and a concurrent asset sale to Ninjour Health International Limited (an affiliate of Biorad Medisys) for $2.25 million, subject to closing conditions.

Key Financial Metrics

Note: Net income for Q1 2025 is primarily driven by a non-cash gain of $3.661 million on changes in the fair value of liability warrants.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 42.7% year-over-year to $1.113 million, attributed to reduced sales volume due to competition from GLP-1 pharmaceuticals.
• Profitability Shift: The company reported a net income of $1.474 million compared to a net loss of $2.193 million in the prior year. This reversal is almost entirely due to a $3.661 million non-cash gain on warrant liability valuation, masking an underlying operating loss of $2.206 million.
• Expense Reduction: Operating expenses decreased 14.5% to $2.887 million. Sales and marketing expenses dropped 48.1% due to a shift to targeted digital marketing and reduced payroll. R&D expenses fell 24.8% as clinical trials were paused to preserve cash.
• Liquidity Improvement: Cash and cash equivalents increased from $0.693 million to $2.515 million following a February 2025 public offering that raised approximately $4.8 million in net proceeds. The company also repaid $0.811 million in convertible debt.
• Transaction Costs: The company incurred $0.367 million in transaction costs related to the pending merger and asset sale, a new line item not present in Q1 2024.

Guidance, Outlook, and Risks

• Going Concern: Management states that based on available cash resources, the company may not have sufficient funds to operate for more than 12 months from the filing date, raising substantial doubt about its ability to continue as a going concern.
• Merger and Asset Sale: The company anticipates closing the merger with Vyome and the asset sale to Biorad in the second quarter of 2025. If completed, the combined company will focus on Vyome's immuno-inflammatory assets, while Biorad assumes ReShape's existing assets and liabilities.
• Capital Needs: The company expects to incur net losses and negative cash flows from operations in 2025 and will likely need to raise additional capital. There is no assurance that financing will be available on acceptable terms.
• Legal Proceedings: A proposed class action lawsuit in Canada alleges the Lap-Band device causes complications. The company has not been formally served, and no liability is currently deemed probable or estimable.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including insufficient accounting resources, lack of management review, and segregation of duties conflicts.

Investor Verification Checklist

• Merger Closing Status: Verify if the merger with Vyome and the asset sale to Biorad have closed or if conditions (e.g., Nasdaq approval, stockholder votes) remain outstanding.
• Cash Runway: Confirm current cash burn rates and whether the $2.5 million cash balance is sufficient to fund operations until the merger closes or additional financing is secured.
• Warrant Liability Volatility: Assess the impact of the $3.661 million non-cash gain on warrant valuation on future earnings, as this is a recurring volatility factor.
• Legal Exposure: Monitor the status of the Canadian class action lawsuit regarding the Lap-Band device for any updates on service of process or settlement discussions.
• Reverse Stock Split: Note the 1-for-25 reverse stock split effective May 9, 2025, and verify share count adjustments in subsequent filings.